Agile Therapeutics, Inc. (NASDAQ: AGRX) is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products that provide women with greater convenience and facilitate compliance. The company’s lead product candidate, Twirla®, is a once-weekly prescription contraceptive patch currently in phase III clinical development. Twirla is based on Agile’s proprietary transdermal patch technology, Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, visit the company’s website at www.agiletherapeutics.com.